Exact Sciences to Host Webcast and Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exact Sciences (EXAS) Drops Another 20%
October 8, 2015 11:25 AM EDTExact Sciences (NASDAQ: EXAS) shares declined another 20% on Thursday, falling to under $8 per share.
Whitney Tilson Says Exact Sciences (EXAS) Still a Great Short
October 7, 2015 10:20 AM EDTHedge fund manager Whitney Tilson said Exact Sciences (NASDAQ: EXAS) is a great short at $10. Link
Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines
October 7, 2015 6:50 AM EDTMizuho Securities maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target on price target to $12.00 (from $35.00), after USPSTF Cologuard guidelines have hampered visibility and added risk. Cologuard was only listed as an alternative colorectal screening test for the average-risk... More
Exact Sciences (EXAS) PT Lowered to $15 at Roth Capital, Recommends Buying on Weakness
October 6, 2015 12:14 PM EDTRoth Capital analyst Chris Lewis lowered his price target on Exact Sciences (NASDAQ: EXAS) to $15.00 (from $31.00) after the USPSTF draft recommendation has designated Cologuard as an alternative rather than recommended test. The firm maintained a Buy rating ad is telling clients to buy on... More
Exact Sciences (EXAS) PT Slashed to $11 at Goldman Sachs on Negative USPSTF Ruling
October 6, 2015 9:32 AM EDTGoldman Sachs analyst Isaac Ro reiterated a Neutral rating and slashed his price target on Exact Sciences (NASDAQ: EXAS) to $11.00 (from $24.00) after the United States Preventative Services Task Force (USPSTF) issued a draft recommendation that included commentary that they view as negative... More
Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines
October 6, 2015 8:45 AM EDTCanaccord Genuity reiterated a Buy rating and $26.00 price target on Exact Sciences (NASDAQ: EXAS) following USPSTF's draft recommendation for colorectal screening guidelines. the report surprisingly did not include Cologuard as an "A" or "B" rated test, though it did mention it as an "alternative screening test" which EXAS interprets as being included in the... More
